<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02488525</url>
  </required_header>
  <id_info>
    <org_study_id>2015_06</org_study_id>
    <secondary_id>2015-001231-20</secondary_id>
    <secondary_id>PHRC-14-0469</secondary_id>
    <nct_id>NCT02488525</nct_id>
  </id_info>
  <brief_title>Prevention of Hemorrhage After Implantation of Mechanical Circulatory Support</brief_title>
  <acronym>PHAM</acronym>
  <official_title>Prevention of Hemorrhage After Implantation of Mechanical Circulatory Support</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Laboratoire français de Fractionnement et de Biotechnologies</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Main objective of the study is to demonstrate that a prophylactic treatment with VWF factor&#xD;
      concentrate after implantation of continuous-flow left ventricular assist device (CF-LVAD)&#xD;
      reduces the frequency of clinically significant bleeding within 3 months after implantation&#xD;
      in comparison to the usual care. Adult patients with functional defects of VWF measured after&#xD;
      implantation of continuous LVAD are randomly assigned to prophylactic treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This time point was chosen because the bleeding events are maximal within the first 3 months&#xD;
      after implantation.&#xD;
&#xD;
        -  Adult patients &gt; 18 years who need a CF-LVAD due to advanced heart failure.&#xD;
&#xD;
        -  Functional To determine the potential indication of Wilfactin® in the field of CF-LVAD&#xD;
           and avoid widespread use and to establish evidence-based recommendation To improve the&#xD;
           knowledge of the role of VWF concentrate in bleeding and angiogenesis after CF-LVAD&#xD;
           implantation and to provide some results about mechanism involved angiogenesis or&#xD;
           hemostasis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    deficient inclusion&#xD;
  </why_stopped>
  <start_date type="Actual">January 20, 2016</start_date>
  <completion_date type="Actual">September 5, 2018</completion_date>
  <primary_completion_date type="Actual">September 5, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with clinically significant bleeding within 3 months after implantation</measure>
    <time_frame>3 months</time_frame>
    <description>A clinically significant bleeding event is defined as internal or external bleeding leading to death or prolonged hospitalization or requiring re-hospitalization, surgery or transfusion of at least 3 units of packed red blood cells or hemoglobin drop&gt; 3g/dL and/or refractory to conventional approach</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Wilfactin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prophylactic treatment with Wilfactin after implantation of continuous-flow left ventricular assist device reduces the frequency of bleeding in comparison to the usual care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The control group will receive all treatments according to standard of care which does not include prophylactic administration of Wilfactin®</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prophylactic treatment with Wilfactin</intervention_name>
    <description>Prophylactic treatment with Wilfactin after implantation of continuous-flow left ventricular assist device reduces the frequency of bleeding in comparison to the usual care.</description>
    <arm_group_label>Wilfactin</arm_group_label>
    <other_name>Prophylactic treatment with VWF factor concentrate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients &gt; 18 years who need a CF-LVAD due to advanced heart failure.&#xD;
&#xD;
          -  Functional defects of VWF measured between day 2 and day 4 after implantation (either&#xD;
             PFA-ADP closure time &gt;180 sec and or VWF:Act/VWF:Ag≤ 0.7)&#xD;
&#xD;
          -  Informed consent of the patient or support person in case of disability at baseline&#xD;
             (patient intubated and ventilated)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Treatment with Wilfactin® within the last seven days&#xD;
&#xD;
          -  Previous adverse reaction to Wilfactin®&#xD;
&#xD;
          -  Absence of functional defects of VWF measured between day 2 and day 4 after&#xD;
             implantation (either PFA-ADP closure time &gt;250 sec and or VWF:Act/VWF:Ag&lt;0.7)&#xD;
&#xD;
          -  Patient with a known thrombophilia&#xD;
&#xD;
          -  Patient with a known severe bleeding disorder&#xD;
&#xD;
          -  Patient refusal or environment&#xD;
&#xD;
          -  Minor patients&#xD;
&#xD;
          -  Pregnant women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susen Sophie, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHRU,</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Vincentelli A, Susen S, Le Tourneau T, Six I, Fabre O, Juthier F, Bauters A, Decoene C, Goudemand J, Prat A, Jude B. Acquired von Willebrand syndrome in aortic stenosis. N Engl J Med. 2003 Jul 24;349(4):343-9.</citation>
    <PMID>12878741</PMID>
  </reference>
  <reference>
    <citation>Van Belle E, Rauch A, Vincentelli A, Jeanpierre E, Legendre P, Juthier F, Hurt C, Banfi C, Rousse N, Godier A, Caron C, Elkalioubie A, Corseaux D, Dupont A, Zawadzki C, Delhaye C, Mouquet F, Schurtz G, Deplanque D, Chinetti G, Staels B, Goudemand J, Jude B, Lenting PJ, Susen S. Von Willebrand factor as a biological sensor of blood flow to monitor percutaneous aortic valve interventions. Circ Res. 2015 Mar 27;116(7):1193-201. doi: 10.1161/CIRCRESAHA.116.305046. Epub 2015 Feb 10.</citation>
    <PMID>25670067</PMID>
  </reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 1, 2015</study_first_submitted>
  <study_first_submitted_qc>July 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2015</study_first_posted>
  <last_update_submitted>July 9, 2019</last_update_submitted>
  <last_update_submitted_qc>July 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acquired Von Willebrand</keyword>
  <keyword>Gastro-intestinal bleeding</keyword>
  <keyword>LVAD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

